Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Annovis Bio IncANVS-1.990.00-28.220.00-453.01%-13.66%33.17$9.76$1.095,261$8.37

Detail of Annovis Bio Inc

 
CEO
Dr. Maria L. Maccecchini Ph.D.
Employees
6
Industry
Biotechnology
Sector
Healthcare
Market cap
$95M

Company details

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Annovis Bio Inc
ANVS • XNYS • US
$8 .37
-2.25 (-21.21%)
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$4.20
Margin profit
0.00%
52 week low
$4.80
52 week high
$19.620001
50-day simple moving average
$8.51
200-day simple moving average
$8.67
Percent held by insiders
21.56%
Percent held by institutions
8.11%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
ANVS -21.21%
eps change
ANVS 0.00%